The frequency of SF mutations in the total AML cohort. The percentage of patients with SF mutations among the total number of AML cases in this study (N = 1447) is shown. The number of cases evaluated for each gene is shown in supplemental Table 2. Cumulatively, SF mutations were identified in 22% of evaluated cases, including 148 individuals with an SRSF2 mutation, 41 patients with an SF3B1 mutation, 31 individuals with a U2AF1 mutation, and 15 patients with a ZRSR2 mutation. Furthermore, 2 patients with an SF1 mutation and 1 patient with SF3A1 and U2AF2 mutations were found.